What medication is appropriate for an adult with concurrent anxiety and pain?

Medication for Concurrent Anxiety and Pain

For adults with concurrent anxiety and pain, duloxetine (starting 30-60 mg daily, increasing to 60-120 mg daily) is the first-line medication choice, as it effectively addresses both conditions simultaneously with moderate-to-high certainty evidence. 1

Primary Recommendation: Duloxetine

Duloxetine stands out as the single most evidence-based option for this dual presentation. A 2023 Cochrane network meta-analysis examining all antidepressants across chronic pain conditions found duloxetine consistently ranked highest with moderate-to-high certainty evidence for pain relief, while also demonstrating small but significant effects on mood 1. Importantly, standard dose (60 mg) was equally efficacious as higher doses across outcomes, so there's no need to push beyond 60 mg unless clearly inadequate 1.

The analgesic effect of duloxetine is independent of its antidepressant activity—it works at lower doses than needed for depression and acts faster for pain 2. This is crucial because most pain studies excluded patients with significant depression, yet duloxetine still improved subclinical anxiety/mood scores 1.

Alternative First-Line Options

If Duloxetine Fails or Is Contraindicated:

Gabapentinoids (gabapentin or pregabalin) are the next choice, particularly if the pain has a neuropathic component:

• Gabapentin: Start 100-300 mg nightly, titrate to 900-3600 mg daily in divided doses 2
• Pregabalin: Start 50 mg three times daily, increase to 100 mg three times daily (max 600 mg/day) 2
• Pregabalin has FDA approval for both generalized anxiety disorder and neuropathic pain, making it particularly suitable for this dual indication 3
• Recent real-world evidence shows gabapentinoids achieved clinically meaningful pain control in patients with concurrent anxiety 4

Tricyclic Antidepressants (TCAs):

Use secondary amines (nortriptyline or desipramine) over tertiary amines due to better tolerability:

• Start 10-25 mg nightly, increase to 50-150 mg nightly 2, 5
• While tertiary amines (amitriptyline, imipramine) may be slightly more efficacious, their anticholinergic burden (sedation, dry mouth, urinary retention) makes them less suitable for routine use 2

SSRIs for Anxiety-Predominant Presentations:

If anxiety is the dominant symptom with milder pain, selective serotonin reuptake inhibitors (SSRIs) provide clinically meaningful anxiety relief 4. However, they lack the robust pain efficacy of duloxetine or gabapentinoids 6, 1.

Critical Dosing Principles

Start low and titrate slowly, especially in older or medically frail patients:

• Increase doses every 3-5 days for TCAs 2
• Increase gabapentin by 50-100% every few days 2
• Continue titration until achieving analgesic effect, encountering intolerable side effects, or reaching conventional maximum dose 2

Adjust for renal insufficiency with gabapentinoids 2.

What NOT to Do

Avoid benzodiazepines for chronic anxiety with pain:

• Not recommended due to adverse effects, especially long-term 7
• In the 2025 Medicare home health study, opioid/benzodiazepine combinations were associated with worse pain control 4
• If acute anxiety bridging is needed while awaiting antidepressant effect, use short-acting benzodiazepines temporarily only 8

Avoid opioid monotherapy for this presentation—it doesn't address the anxiety component and recent evidence shows CNS polypharmacy including opioids worsens pain outcomes 4.

Combination Strategies

For refractory cases, combine duloxetine or an SSRI/SNRI with a gabapentinoid rather than adding benzodiazepines 8. The 2025 Medicare study found that drug combinations excluding opioid/benzodiazepine pairs achieved better pain reduction 4.

Consider topical agents as adjuncts for focal or regional pain:

• Lidocaine 5% patch applied daily 2, 5
• Diclofenac gel three times daily 2
• These act locally with minimal systemic absorption and can be combined with systemic agents 2

Special Considerations

For patients with substance use disorder (40% prevalence in the Medicare cohort 4):

• Avoid benzodiazepines entirely
• Consider atypical antipsychotics (aripiprazole, quetiapine) as augmentation if needed 8

For chronic musculoskeletal pain with anxiety, duloxetine remains first-line, with gabapentin and SNRIs specifically useful for comorbid chronic pain syndromes 8.

Patient education is essential: Emphasize the trial-and-error nature of treatment to prevent discouragement 2. Explain that analgesic doses are often lower than antidepressant doses and work faster for pain 2.

Monitoring and Adjustment

Reassess at 2-4 weeks. If ineffective, discontinue and try the next agent—don't continue medications that aren't working 5. The evidence shows high discontinuation rates (34% purchased only one prescription of pregabalin, with persistence declining rapidly) 3, suggesting the importance of finding the right medication quickly.

Most evidence is for short-term outcomes (average 10 weeks) 1, so long-term monitoring remains essential despite limited data on sustained efficacy.